We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+5.31%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$999M
AUM Growth
+$357M
Cap. Flow
+$419M
Cap. Flow %
41.94%
Top 10 Hldgs %
54.5%
Holding
94
New
23
Increased
23
Reduced
18
Closed
26

Top Buys

Rank Stock Value
1
SNN icon
Smith & Nephew
SNN
+$20.4M
2
APEN
Apollo Endosurgery, Inc.
APEN
+$20M
3
KYNB
Kyntra Bio
KYNB
+$19.3M
4
NRIX icon
Nurix Therapeutics
NRIX
+$14.5M
5
ORGO icon
Organogenesis Holdings
ORGO
+$14.4M

Top Sells

Rank Stock Value
1
FLXN
Flexion Therapeutics, Inc.
FLXN
+$12.7M
2
NEO icon
NeoGenomics
NEO
+$9.19M
3
CDNA icon
CareDx
CDNA
+$8.03M
4
HOWL icon
Werewolf Therapeutics
HOWL
+$7.53M
5
CCCC icon
C4 Therapeutics
CCCC
+$7.49M

Sector Composition

Rank Sector Weight
1 Healthcare 70.82%
2 Financials 0.64%
3 Consumer Staples 0%
4 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTSO icon
76
Cytosorbents Corp
CTSO
$25M
– –
-800,000
Closed -$6.5M
EDIT icon
77
Editas Medicine
EDIT
$445M
– –
-23,500
Closed -$965K
EWTX icon
78
Edgewise Therapeutics
EWTX
$4.78B
– –
-31,300
Closed -$520K
FDMT icon
79
4D Molecular Therapeutics
FDMT
$552M
– –
-120,900
Closed -$3.26M
GLUE icon
80
Monte Rosa Therapeutics
GLUE
$1.33B
– –
-25,000
Closed -$557K
LUNG icon
81
Pulmonx
LUNG
$88M
– –
-87,612
Closed -$3.15M
NEO icon
82
NeoGenomics
NEO
$2B
– –
-190,556
Closed -$9.19M
PRCT icon
83
Procept Biorobotics
PRCT
$1.14B
– –
-20,000
Closed -$763K
RFL icon
84
Rafael Holdings
RFL
$105M
– –
-22,046
Closed -$668K
SKIN icon
85
SkinHealth Systems
SKIN
$99.5M
– –
-201,994
Closed -$5.25M
TVTX icon
86
Travere Therapeutics
TVTX
$5.89B
– –
-210,815
Closed -$5.11M
CDMO
87
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
– –
-135,000
Closed -$2.91M
EIGR
88
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-7,117
Closed -$1.43M
SLGC
89
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
– –
-422,243
Closed -$5.23M
VIVO
90
DELISTED
Meridian Bioscience Inc
VIVO
– –
-163,000
Closed -$3.14M
ITMR
91
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
– –
-180,839
Closed -$5.46M
FLXN
92
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-2,084,050
Closed -$12.7M
INBX
93
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-97,979
Closed -$3.26M
1 2 3
4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Soleus Capital Management held 94 positions worth $999M, up 56% from $642M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Soleus Capital Management deployed $419M of net new capital in Q4 2021, opening 23 new positions and adding to 23 existing holdings. Its largest new stake was Smith & Nephew: 593,200 shares worth $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 92% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Werewolf Therapeutics, an estimated $7.53M trimmed.

  • Soleus Capital Management's largest Q4 2021 buy was Smith & Nephew: 593,200 shares worth $20.5M.
  • Soleus Capital Management added most to Nurix Therapeutics in Q4 2021, an estimated $14.5M increase.
  • Soleus Capital Management's biggest Q4 2021 reduction was Werewolf Therapeutics, cutting an estimated $7.53M.
  • Soleus Capital Management fully exited Flexion Therapeutics, Inc. in Q4 2021, selling an estimated $12.7M.
  • Soleus Capital Management's ten largest holdings make up 54% of its $999M portfolio in Q4 2021.
  • Soleus Capital Management opened 23 new positions and closed 26 in Q4 2021.
  • Soleus Capital Management's portfolio value rose 56% quarter-over-quarter to $999M.

Based on Soleus Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.